Fused tricyclic ring derivatives as SRC homology-2 phosphatase inhibitors

Abstract

The present disclosure provides certain fused tricyclic ring derivatives that are Src Homology-2 phosphatase (SHP2) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition of SHP2. Also provided are pharmaceutical compositions containing such compounds and processes for preparing such compounds.

Dependencies are inferred from the claim text.